This Article Full Text Full Text (PDF) CME: Take the course for this article: Management of Treatment-Related Toxicity in Advanced Ovarian Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunton, C. J. Search for Related Content PubMed PubMed Citation Articles by Dunton, C. J.

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA

Correspondence: Charles J. Dunton, M.D., Professor of Obstetrics and Gynecology, Albert Einstein Medical Center, Department of Obstetrics and Gynecology, 5501 Old York Road, Philadelphia, Pennsylvania 19141, USA. Telephone: 215-456-8386; Fax: 215-456-2386; e-mail: duntonc{at}einstein.edu

Recognition of recurrent ovarian cancer as a disease with significant secondary responses and remissions has led to an increase in the need for oncologists to plan for the long-term therapy of patients. However, many of the currently available front-line and salvage agents used in advanced ovarian cancer are associated with cumulative and/or irreversible toxicities that pose challenges in long-term planning. The irreversible effects associated with some of these therapies may render patients less tolerant to subsequent treatments and lead to a cycle of diminishing treatment options with each remission and disease relapse. Additionally, the potential for patients to experience cumulative toxicity must be carefully weighed against the goals of prolonging the disease-free interval and improving patient quality of life. A number of agents are available in the treatment armamentarium (platinum, paclitaxel, gemcitabine, etoposide, liposomal doxorubicin, and topotecan), many, but not all of which are associated with cumulative toxicity. For instance, cumulative neurotoxicity associated with cisplatin as first-line therapy may diminish the option for retreatment with platinum at first relapse. In contrast, the main toxicity associated with topotecan is noncumulative, manageable myelosuppression. In this review, the major toxicities associated with the predominant chemotherapy agents used in advanced ovarian cancer are discussed along with selected management approaches in the context of long-term treatment planning and sequencing.

Key Words. Doxorubicin • Drug toxicity • Neutropenia • Ovarian neoplasms • Topotecan • Etoposide

This article has been cited by other articles:

				D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis Oncologist, October 1, 2005; 10(9): 686 - 694. [Abstract] [Full Text] [PDF]

				J. R. Eckardt Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer Oncologist, December 1, 2004; 9(suppl_6): 25 - 32. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan Oncologist, October 1, 2002; 7(90005): 1 - 2. [Full Text] [PDF]

				D. K. Armstrong Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease Oncologist, October 1, 2002; 7(90005): 20 - 28. [Abstract] [Full Text] [PDF]

				R. Morris and A. Munkarah Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 29 - 35. [Abstract] [Full Text] [PDF]

				R. L. Coleman Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary Oncologist, October 1, 2002; 7(90005): 46 - 55. [Abstract] [Full Text] [PDF]